Business Monitor Online | Mylan Launches Mesalamine Generic in US

Alston & Bird client Mylan Pharmaceuticals Inc. won a significant patent ruling against Shire Development LLC when a Florida federal judge vacated her earlier decision on reconsideration and found that Mylan’s proposed generic version of Shire’s gastrointestinal drug Lialda does not infringe U.S. Patent Number 6,773,720.

Jim Grant, Lance Soderstrom, and Joseph Janusz are mentioned for representing Mylan Pharmaceuticals Inc. in a generic drug patent dispute with Shire Development LLC.